By otakuyassine3@gmail.com 
Pediatrix Medical Group, Inc. (NYSE:MD – Get Free Report) saw a significant decrease in short interest in November. As of November 30th, there was short interest totalling 2,980,000 shares, a decrease of 21.0% from the November 15th total of 3,770,000 shares. Approximately 3.5% of the company’s shares are sold short. Based on an average daily trading volume, of 674,100 shares, the short-interest ratio is currently 4.4 days.
Insider Buying and Selling
In related news, Director Mark S. Ordan sold 27,600 shares of the stock in a transaction dated Wednesday, November 13th. The shares were sold at an average price of $15.35, for a total value of $423,660.00. Following the completion of the transaction, the director now directly owns 138,683 shares of the company’s stock, valued at $2,128,784.05. This represents a 16.60 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, EVP Mary Ann E. Moore sold 8,108 shares of the stock in a transaction dated Friday, November 8th. The stock was sold at an average price of $16.00, for a total transaction of $129,728.00. Following the completion of the transaction, the executive vice president now directly owns 135,810 shares of the company’s stock, valued at approximately $2,172,960. The trade was a 5.63 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 2.00% of the stock is owned by insiders.
Institutional Investors Weigh In On Pediatrix Medical Group
Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Nisa Investment Advisors LLC raised its position in shares of Pediatrix Medical Group by 47.2% during the 2nd quarter. Nisa Investment Advisors LLC now owns 4,755 shares of the company’s stock valued at $36,000 after purchasing an additional 1,524 shares during the period. SummerHaven Investment Management LLC increased its holdings in Pediatrix Medical Group by 3.8% in the 2nd quarter. SummerHaven Investment Management LLC now owns 55,951 shares of the company’s stock valued at $422,000 after acquiring an additional 2,069 shares during the last quarter. Innealta Capital LLC bought a new stake in Pediatrix Medical Group in the 2nd quarter valued at $33,000. nVerses Capital LLC bought a new stake in shares of Pediatrix Medical Group in the 2nd quarter worth about $31,000. Finally, Ballentine Partners LLC bought a new stake in shares of Pediatrix Medical Group in the 2nd quarter worth about $132,000. Hedge funds and other institutional investors own 97.71% of the company’s stock.
Pediatrix Medical Group Stock Down 0.7 %
Shares of NYSE:MD traded down $0.10 during trading on Friday, reaching $14.07. 323,416 shares of the stock traded hands, compared to its average volume of 851,323. The stock has a 50-day moving average of $13.96 and a two-hundred day moving average of $10.78. Pediatrix Medical Group has a 52-week low of $6.62 and a 52-week high of $16.41. The company has a debt-to-equity ratio of 0.83, a quick ratio of 1.42 and a current ratio of 1.42. The stock has a market cap of $1.21 billion, a P/E ratio of -4.60, a price-to-earnings-growth ratio of 2.02 and a beta of 1.57.
Pediatrix Medical Group (NYSE:MD – Get Free Report) last issued its earnings results on Friday, November 1st. The company reported $0.44 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.37 by $0.07. Pediatrix Medical Group had a negative net margin of 12.65% and a positive return on equity of 12.79%. The company had revenue of $511.20 million for the quarter, compared to analysts’ expectations of $498.87 million. During the same quarter last year, the company posted $0.29 earnings per share. The firm’s quarterly revenue was up .9% on a year-over-year basis. As a group, sell-side analysts expect that Pediatrix Medical Group will post 1.26 earnings per share for the current fiscal year.
Wall Street Analyst Weigh In
A number of equities analysts have weighed in on MD shares. StockNews.com raised shares of Pediatrix Medical Group from a “hold” rating to a “buy” rating in a research note on Wednesday. Jefferies Financial Group raised their target price on shares of Pediatrix Medical Group from $14.00 to $18.00 and gave the company a “buy” rating in a research note on Tuesday, November 5th. UBS Group raised their target price on shares of Pediatrix Medical Group from $10.50 to $16.50 and gave the company a “neutral” rating in a research note on Tuesday, November 5th. Truist Financial raised their target price on shares of Pediatrix Medical Group from $13.00 to $16.00 and gave the company a “hold” rating in a research note on Monday, November 4th. Finally, Mizuho increased their price target on shares of Pediatrix Medical Group from $13.00 to $15.00 and gave the company a “neutral” rating in a report on Tuesday, November 19th. Four research analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. Based on data from MarketBeat.com, Pediatrix Medical Group presently has an average rating of “Hold” and an average price target of $16.10.
View Our Latest Stock Report on MD
Pediatrix Medical Group Company Profile
Pediatrix Medical Group, Inc, together with its subsidiaries, provides newborn, maternal-fetal, pediatric cardiology, and other pediatric subspecialty care services in the United States. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians.
Read More
Receive News & Ratings for Pediatrix Medical Group Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Pediatrix Medical Group and related companies with MarketBeat.com’s FREE daily email newsletter.